PRTK Paratek Pharmaceuticals Inc.

4.36
+0.19  (+5%)
Previous Close 4.17
Open 4.21
Price To Book -10.38
Market Cap 141,853,782
Shares 32,535,271
Volume 294,171
Short Ratio
Av. Daily Volume 332,315

NewsSee all news

  1. Edited Transcript of PRTK earnings conference call or presentation 6-Aug-19 8:30pm GMT
  2. Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Tops Revenue Estimates
  3. Paratek Pharmaceuticals Generates Net Revenues of $2.0 Million in the Second Quarter of 2019
  4. Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
  5. Paratek Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 6, 2019

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved November 23, 2011.
Intermezzo
Insomnia
Phase 3 data released July 17, 2017 - all endpoints met.
Omadacycline - oral
Acute bacterial skin and skin structure infections (ABSSSI)
FDA Approval announced October 2, 2018.
Omadacycline
Acute bacterial skin and skin structure infections (ABSSSI)
FDA Approval announced October 2, 2018.
Omadacycline
Community-acquired bacterial pneumonia (CABP)
FDA Approval announced October 2, 2018.
Sarecycline
Severe acne vulgaris
Phase 2 data due 4Q 2019.
Omadacycline
Urinary tract infections
Phase 2 data due 4Q 2019.
Omadacycline
Complicated urinary tract infections (cUTI) / acute pyelonephritis

Latest News

  1. Edited Transcript of PRTK earnings conference call or presentation 6-Aug-19 8:30pm GMT
  2. Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Tops Revenue Estimates
  3. Paratek Pharmaceuticals Generates Net Revenues of $2.0 Million in the Second Quarter of 2019
  4. Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
  5. Paratek Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 6, 2019
  6. Earnings Preview: Paratek Pharmaceuticals (PRTK) Q2 Earnings Expected to Decline
  7. Melinta (MLNT) Announces Preliminary Product Sales for Q2
  8. What Type Of Shareholder Owns Paratek Pharmaceuticals, Inc.'s (NASDAQ:PRTK)?
  9. Here’s What Hedge Funds Think About Paratek Pharmaceuticals Inc (PRTK)
  10. X-Biotix Therapeutics Joins Antimicrobials Working Group
  11. Paratek Pharmaceuticals Promotes Evan Loh, M.D. to Chief Executive Officer; Michael Bigham to Assume Role of Executive Chairman
  12. Biotech companies dominate fastest-growing public companies list again
  13. Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019
  14. Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections
  15. Edited Transcript of PRTK earnings conference call or presentation 8-May-19 8:30pm GMT
  16. Paratek: 1Q Earnings Snapshot
  17. Paratek’s NUZYRA™ (omadacycline) Generates Net Sales of $1.3 Million in the First Eight Weeks on the U.S. Market
  18. Analysts Estimate Paratek Pharmaceuticals (PRTK) to Report a Decline in Earnings: What to Look Out for
  19. Paratek Pharmaceuticals to Report First Quarter 2019 Financial Results on May 8, 2019